Use of a compound that is a ligand for the alpha 7 nicotinic acetylcholine receptor in the manufacture of a medicament for the treatment of psoriasis and formulations thereof
By using the α7 nicotinic acetylcholine receptor allosteric agonist GAT107, the issues of limited efficacy and safety in psoriasis treatment have been resolved. Effective treatment results have been achieved through oral administration, reducing spleen-to-body ratio, epidermal thickness, and inflammatory factor levels, and improving the inflammatory response at the lesion site.
CN122376592APending Publication Date: 2026-07-14BEIJING LIFE SCIENCE ACADEMY CO LTD
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- BEIJING LIFE SCIENCE ACADEMY CO LTD
- Filing Date
- 2026-06-09
- Publication Date
- 2026-07-14
Smart Images
Figure CN122376592A_ABST
Abstract
The application relates to the technical field of compound new use, in particular to application of a ligand compound of an alpha 7 nicotinic acetylcholine receptor in preparation of a medicine for treating psoriasis and a preparation thereof. Pharmacological experiment results show that an allosteric agonist GAT107 of the alpha 7 nicotinic acetylcholine receptor reduces the spleen / body ratio, the epidermis thickness, the inflammatory factor level in the lesion tissue, the keratinocyte proliferation level of a psoriasis mouse model, reduces the recruitment of inflammatory cells to the lesion to release inflammatory factors, and can effectively treat psoriasis.
Need to check novelty before this filing date? Find Prior Art